> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Grants EUA for Novavax Covid Vaccine
- URL: https://www.fdaweb.com/fda-grants-eua-for-novavax-covid-vaccine/
- Published: 2022-07-13T12:00:00.000Z
- Updated: 2026-09-14T17:51:38.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5152270

FDA has granted an emergency use authorization for Novavax’s Covid-19 Vaccine, Adjuvanted for preventing disease caused by severe acute respiratory syndrome coronavirus 2 in individuals 18 years of age and older. This is the fourth Covid vaccine permitted for use in the U.S., joining vaccines from Pfizer/BioNTech, Moderna and Janssen.

“Today’s authorization offers adults in the United States who have not yet received a Covid-19 vaccine another option that meets the FDA’s rigorous standards for safety, effectiveness and manufacturing quality needed to support emergency use authorization,” FDA commissioner **Robert Califf** is quoted in a [release](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-emergency-use-novavax-covid-19-vaccine-adjuvanted?ref=fdaweb.com) as saying. Because the vaccine is based on older manufacturing technologies, many health experts see it as an option to those who can’t or won’t take a mRNA-based vaccine.

The Novavax vaccine is administered as a two-dose primary series over three weeks. Approval is based on data from a study conducted in the U.S. and Mexico. “Overall, the vaccine was 90.4% effective in preventing mild, moderate or severe Covid-19, with 17 cases of Covid-19 occurring in the vaccine group and 79 cases in the placebo group,” the agency says. “No cases of moderate or severe Covid-19 were reported in participants who received the vaccine, compared with nine cases of moderate Covid-19 and four cases of severe Covid-19 reported in placebo recipients. In the subset of participants 65 years of age and older, the vaccine was 78.6% effective.” FDA noted that the trial was conducted before the delta and omicron variants emerged.